GILD 2Q20 HCV sales=$448M, -39% QoQ, -41% YoY. The 2Q20 geographic breakdown was: US $220M; EU $70M; RoW $158M.
During 2Q20, the COVID-19 pandemic greatly reduced HCV patient visits and hence new-patient starts, worldwide. GILD’s worldwide HCV patient starts in 2Q20 (CC slide #16) were 25K vs 45K in 1Q20 (decreasing from 29K to 17K in the US).
Market Data 
Markets 
AI
